Current approach in the treatment for resectable esophageal squamous‑cell carcinoma

Esophageal cancer is one of the most aggressive malignancies gastrointestinal tract, characterized by high malignancy potential and poor prognosis. Surgical treatment standard for localized esophageal cancer, but results only surgery locally advanced tumors remain unsatisfactory. The use neoadjuvant chemotherapy, as well chemoradiation therapy, leads to a downstaging tumor, improves its resectability increases an overall disease‑free survival rates. method choice unresectable in case refusal or intolerance surgical treatment, definitive chemoradiotherapy. Until recently, adjuvant therapy after R0 resection was not carried out, however, there evidence that postoperative nivolumab, immune checkpoint inhibitor, significantly progression‑free patients with residual tumor. This article presents current review resectable squamous‑cell carcinoma esophagus.